Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease

NCT03105128 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03105128
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03105128 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Completed
Start date
May 10, 2017
Completion date
April 14, 2021
Enrollment
931 (actual)
Sites
475

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease